Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Prevention of Ethanol-Induced Liver Injury in Rats by an Agonist of Peroxisome Proliferator-Activated Receptor-γ, Pioglitazone

Nobuyuki Enomoto, Yoshiyuki Takei, Miyoko Hirose, Akira Konno, Tomoyoshi Shibuya, Shujiro Matsuyama, Satoko Suzuki, Kenichi Ikejima Tsuneo Kitamura and Nobuhiro Sato
Journal of Pharmacology and Experimental Therapeutics September 2003, 306 (3) 846-854; DOI: https://doi.org/10.1124/jpet.102.047217
Nobuyuki Enomoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiyuki Takei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miyoko Hirose
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Konno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoyoshi Shibuya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shujiro Matsuyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoko Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenichi Ikejima Tsuneo Kitamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nobuhiro Sato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Agonists of peroxisome proliferator-activated receptor (PPAR)-γ have been shown to reduce tumor necrosis factor-α (TNF-α)-induced insulin resistance. On the other hand, sensitization of Kupffer cells to lipopolysaccharide (LPS) and their production of TNF-α are critical for progression of alcoholic liver injury. This study was intended to determine whether pioglitazone, a PPAR-γ agonist, could prevent alcohol-induced liver injury. Rats were given ethanol (5 g/kg b.wt.) and pioglitazone (500 μg/kg) once every 24 h intragastrically. Ethanol for 8 weeks caused pronounced steatosis, necrosis, and inflammation in the liver. These pathological parameters were diminished greatly by pioglitazone. Kupffer cells were sensitized to LPS after ethanol for 4 weeks as evidenced by aggravation of liver pathology induced by LPS (5 mg/kg) and enhancement of LPS (100 ng/ml)-induced intracellular Ca2+ concentration elevation in Kupffer cells. The parameters were diminished by treatment with pioglitazone. LPS-induced TNF-α production by Kupffer cells from the 4-week ethanol group was 3 to 4 times higher than control. This increase was blunted by 70% with pioglitazone. Gut permeability was 10-fold higher in the 4-week ethanol group, and pioglitazone treatment did not change the value. Inclusion of TNF-α in culture media of Kupffer cells enhanced CD14 expression, LPS-induced intracellular Ca2+ concentration response, and production of TNF-α. These results indicate that pioglitazone prevents alcoholic liver injury through abrogation of Kupffer cell sensitization to LPS.

Sensitization of Kupffer cells is a prominent event in the initiation of alcoholic liver disease (Stahnke et al., 1991; Martinez et al., 1992). Sensitized Kupffer cells are activated by endotoxin (lipopolysaccharide, LPS), leading to a rapid increase in intracellular calcium (Watanabe et al., 1996) followed by release of inflammatory mediators (e.g., cytokines and lipid metabolites), as well as reactive oxygen intermediates (Nolan, 1981; Decker et al., 1989; Shibayama et al., 1991; Wang et al., 1995). Among them, TNF-α is likely a critical factor in the progression of alcoholic liver disease because it induces cell death due to apoptosis and necrosis and stimulates generation of toxic superoxide anion from mitochondrial complex III in parenchymal cells (Schulze-Osthoff et al., 1993) and expression of factors for neutrophil chemotaxis (interleukin-8/cytokine-induced neutrophil chemoattractant, macrophage inflammatory protein, macrophage inflammatory protein-2) and intracellular adhesion molecule-1, leading to microcirculatory disturbance (Hijioka et al., 1991; Oshita et al., 1992; McCuskey et al., 1993). This scenario is supported by the fact that early injury in the Tsukamoto-French enteral model of alcohol induced liver injury, in which high-fat liquid diet is infused continuously intragastrically, is diminished by an anti-TNF-α antibody (Iimuro et al., 1997) and is prevented in TNF-α receptor-knockout mice (Yin et al., 1999). Accordingly, it is postulated that sensitization of Kupffer cells to LPS and overproduction of TNF-α by Kupffer cells are critical for progression of alcoholic liver injury.

On the other hand, peroxisome proliferator-activated receptor (PPAR)-γ is a member of the nuclear hormone receptor superfamily that heterodimerizes with the retinoid X receptor and functions as a transcriptional regulator of a variety of genes. The thiazolidinedione class of antidiabetic drugs was identified as ligands for PPAR-γ, and subsequently they have been shown to reduce TNF-α-induced insulin resistance (Saltiel and Olefsky, 1996). The mechanisms of this action remain obscure, although it has been proposed that PPAR-γ ligands cross talk with several points of signaling pathways evoked by TNF-α (Hofman et al., 1994; Jiang et al., 1998; Murase et al., 1998). The property of PPAR-γ ligands to oppose TNF-α actions suggests that they might be used for treatment of alcoholic liver disease. Accordingly, this study was intended to determine whether pioglitazone, a PPAR-γ agonist, could prevent alcohol-induced liver injury.

Materials and Methods

Animals and Treatments. In this study, we used a model of alcoholic liver injury based on the sensitization of Kupffer cells, in which rats are given ethanol (5 g/kg b.wt. intragastrically) once every 24 h (Enomoto et al., 1999). This model achieves inflammatory and necrotic changes in the liver only in 8 weeks, mimicking clinical alcohol liver injury (Enomoto et al., 1999). These histological manifestations are preceded by sensitization of Kupffer cells to LPS. Accordingly, liver damage was evaluated after 8 weeks of ethanol treatment, whereas evaluation of Kupffer cell sensitization to LPS was performed at 4 weeks (see below). Female Wistar rats weighing 200 to 250 g were fed a liquid diet (Oriental, Tokyo, Japan) in which 35% of the calories were from corn oil and 47% were from maltosedextrin ad libitum. Elements of this diet and percentage of calories were shown elsewhere (Enomoto et al., 1999). Rats were given one single dose of ethanol (5 g/kg) between 10:00 AM and 12:00 PM via an 18-gauge oral biomedical device every 24 h (Wendell and Thurman, 1979; Thurman et al., 1982). Two groups of rats received an oral dose of pioglitazone (500 μg/kg b.wt. i.g., a generous gift from Takeda Chemical Industries, Osaka, Japan) only or concurrently with ethanol.

To assess the sensitization of Kupffer cells to LPS in vivo, LPS (5 mg/kg, Escherichia coli serotype 0111:B4; Sigma-Aldrich, St. Louis, MO) was administered i.v. into either control or ethanol-treated rats, and liver histology was evaluated 24 h later.

All animals were given humane care in compliance with the institutional guidelines. Sera were stored at -20°C, and aspartate transaminase (AST) and alanine aminotransferase (ALT) were measured by standard enzymatic procedures (Bergmeyer, 1988).

Pathological Evaluation. Liver specimens were obtained from rats 24 h after final ethanol on 8 weeks of daily single intragastric treatment with ethanol (5 g/kg) and 24 h after LPS (5 mg/kg) on 4 weeks of ethanol. Livers were fixed in formalin, embedded in paraffin, and stained with hematoxylin and eosin for assessment of steatosis, inflammation, and necrosis (Nanji et al., 1989).

Kupffer Cell Preparation and Culture. Kupffer cells were isolated by collagenase digestion and differential centrifugation using Percoll (Pharmacia AB, Uppsala, Sweden) as described elsewhere with slight modifications (Pertoft et al., 1982). Briefly, the liver was perfused through the portal vein with Ca2+- and Mg2+-free Hanks' balanced salt solution at 37°C for 5 min at a flow rate of 26 ml/min. Subsequently, perfusion was performed with Hanks' balanced salt solution containing 0.025% collagenase IV (Sigma-Aldrich) at 37°C for 5 min. After the liver was digested, it was excised and cut into small pieces in collagenase buffer. The suspension was filtered through nylon gauze mesh and the filtrate was centrifuged at 450g for 10 min at 4°C. Cell pellets were resuspended in buffer, parenchymal cells were removed by centrifugation at 50g for 3 min, and the nonparenchymal cell fraction was washed twice with buffer. Cells were centrifuged on a density cushion of Percoll at 1,000g for 15 min, and the Kupffer cell fraction was collected and washed with buffer again. Viability of cells determined by trypan blue exclusion was >90%. Cells were seeded onto 35-mm glass bottom culture dish (YSI Japan, Tokyo, Japan) and cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and 10 mM HEPES and antibiotics (100 U/ml penicillin G and 100 μg/ml streptomycin sulfate) at 37°C with 5% CO2. Nonadherent cells were removed after 1 h by replacing buffer, and cells were cultured for 24 h before experiments.

Measurement of Intracellular Ca2+ ([Ca2+]i) Using a Fluorescence Microscope Imaging System. All of the experiments were performed after cells were incubated at 37°C for 24 h. Fura- 2/AM with Pluronic F127 was dissolved in phosphate saline solution containing 1.0 mM Ca2+, in which final concentrations of Fura-2/AM and Pluronic F127 were 4 mM and 0.05%, respectively. After loading with Fura-2/AM solution at 37°C for 30 min, Kupffer cells on cover-slips were installed in a fluorescence microscope (Diaphot; Nikon, Tokyo, Japan) with a 100-W xenon arc lamp as a light source. The objective lens was a Nikon Fluor X100. A silicon-intensified target camera (C-2400; Hamamatsu Photonics, Hamamatsu, Japan) was linked to a computer (MAXYDT2; Mitsubishi, Tokyo, Japan) and fluorescence intensity of Fura-2/AM was quantified. Wavelengths of 340 and 380 nm for excitation and 520 nm for emission were used. [Ca2+]i was determined by the following equation (Grynkiewicz et al., 1985): [Ca2+]i = Kd([Ro - Rmin]/[Rmax - Ro])B. Kd, the Ca2+ dissociation constant for Fura-2, was confirmed as 224 nM. R represents fluorescence intensity at 340-nm excitation divided by that at 380-nm excitation (Ro, experimental data; Rmin, R in 2 mM EGTA and 1 mM ionomycin; Rmax is R in 10 mM Ca2+ and 1 mM ionomycin). B is the ratio of fluorescence intensity at 380 nm in the absence of Ca2+ versus a saturating concentration of Ca2+. Because intracellular Ca2+ was calculated from the ratio R, the fading of fluorescence did not interfere with the results.

TNF-α Production by Kupffer Cells. Kupffer cells were seeded onto 24-well plates and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 10 mM HEPES, and antibiotics at 37°C in the presence of 5% CO2. Cells were incubated with fresh medium containing LPS (100 ng/ml supplemented with 5% rat serum) for an additional 4 h. In some experiments, cells were preincubated for 24 h with 10 ng/ml TNF-α before challenge with LPS. Samples of media were collected and kept at -80°C until assay. TNF-α in the culture media was measured using an enzyme-linked immunosorbent assay (ELISA) kit (Genzyme, Cambridge, MA), and data were corrected for dilution.

Western Blotting for CD14 and Tristetraprolin (TTP). Total protein extracts of liver and cultured Kupffer cells were obtained by homogenizing samples in a buffer containing 10 mM HEPES, pH 7.6, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 40 μg/ml bestatin, 20 mM β-glycerophosphate, 10 mM 4-nitrophenylphosphate, 0.5 mM pefabloc, 0.7 μg/ml pepstatin A, 2 μg/ml aprotinin, 50 μM Na3VO4, and 0.5 μg/ml leupeptin. Protein concentration was determined using the Bradford assay kit (Bio-Rad, Hercules, CA). Extracted protein was separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Membranes were blocked by Tris-buffered saline-Tween 20 containing 5% skim milk and probed with a mouse anti-rat ED9 monoclonal antibody (Serotec, Oxford, UK) and a mouse anti rat TTP monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), followed by a horseradish peroxidase (HRP)conjugated secondary antibody as appropriate. Membranes were incubated with a chemiluminescence substrate (ECL reagent; Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK) and exposed to X-OMAT films (Eastman Kodak, Rochester, NY).

Gut Permeability. Gut permeability was measured in isolated segments of ileum from translocation of horseradish peroxidase as described previously (Carter et al., 1987). Briefly, 8-cm segments of ileum were everted, filled with 1 ml of Tris buffer (125 mM NaCl, 10 mM fructose, and 30 mM Tris; pH 7.5), and ligated at both ends. The filled gut segments were incubated in Tris buffer containing 40 mg/100 ml horseradish peroxidase. After 45 min, gut sacs were removed and blotted lightly to eliminate excess horseradish peroxidase and the contents (∼750 μl) of each sac were collected carefully using a 1-ml syringe. Horseradish peroxidase activity in the contents of each sac was determined spectrophotometrically.

Fluorescence Staining of CD14. Kupffer cells were fixed on a plastic dish using cold pure ethanol for 30 s, and the phalloidinrhodamine method (Watanabe et al., 1990) was used for staining actin. Indirect immunofluorescence staining was performed for CD14. They were then incubated overnight with the primary antibody, 1:200 diluted polyclonal rabbit anti-CD14 (M-305; Santa Cruz Biotechnology, Inc.). The secondary antibody used was fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology, Inc.). Samples were evaluated and their appearance was recorded on an Axiophot microscope (Carl Zeiss, Oberkochen, Germany) with Ektachrome Dyna 400 films (Eastman Kodak).

Statistical Analysis. All results were expressed as mean ± S.E.M. Statistical differences between means were determined using analysis of variance (ANOVA) and Bonferroni's post hoc test. p < 0.05 was selected prior to the study to reflect significance.

Results

Effect of Pioglitazone on Ethanol-Induced Liver Injury. There are no differences in body weight growth among control, pioglitazone, ethanol, and ethanol + pioglitazone groups during 8 weeks of ethanol treatment. All animals survived until the end of the 8-week experiment. Animals given pioglitazone only showed completely normal liver histology (Fig. 1B). As reported previously, ethanol administration once every 24 h for 8 weeks caused pronounced steatosis, necrosis, and inflammation in the liver (Fig. 1, C and D). In contrast, these pathological parameters were diminished markedly by the concurrent treatment with pioglitazone (500 μg/kg/day) (Fig. 1E). Furthermore, although mean value of ALT in the control, nontreated rats was 30 ± 6 IU/l, ALT increased 3-fold to 91 ± 7 IU/l in the 8-week ethanol group (Fig. 1, F and G). It is notable that the increase in ALT was blocked almost completely by pioglitazone (41 ± 5 IU/l) (Fig. 1G). Similar results were obtained for AST values (Fig. 1F).

  Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Effect of pioglitazone on ethanol-induced liver injury. Photomicrographs of H&E sections of livers from rats treated as described under Materials and Methods: no treatment (A), 8-week pioglitazone (500 μg/kg i.g., once daily) (B), 8-week ethanol (5 g/kg) (original magnification, 100×) (C), 8-week ethanol (400×) (D), and 8-week ethanol + pioglitazone (100×) (E). Typical photomicrographs. Blood samples were collected from the aorta, and AST (F) and ALT (G) were determined as described under Materials and Methods. Results are mean ± S.E.M. (n = 4-8). *, p < 0.05 versus control. #, p < 0.05 versus 8 weeks of ethanol by ANOVA and Bonferroni's post hoc test.

To exclude the possibility that the protective effect observed is due to alterations of absorption and/or elimination of ethanol, we measured blood ethanol concentration. There were no statistically significant differences in blood ethanol concentrations between groups given either ethanol only or ethanol + pioglitazone (500 μg/kg) 90 min and 6 h postadministration (485 ± 62 versus 440 ± 23 mg/dl and 350 ± 56 versus 367 ± 32 mg/dl, respectively; N.S.).

Effect of Pioglitazone on Ethanol Plus LPS-Induced Liver Injury. ALT/AST values after 4 weeks of ethanol remained unchanged compared with those of normal, untreated rats. Furthermore, there were no significant difference in ALT/AST values among the 4-week ethanol, 4-week pioglitazone, and 4-week ethanol + pioglitazone groups (data not shown).

To assess the sensitization of Kupffer cells to LPS in vivo, LPS (5 mg/kg) was administered i.v. into either control or ethanol-treated rats, and liver histology was evaluated 24 h later. LPS caused focal necrosis and neutrophil infiltration in liver from the control, nontreated rats (Fig. 2A). In the group treated with pioglitazone for 4 weeks, liver histology displayed only slight infiltration of inflammatory cells, but lacking overt necrosis (Fig. 2B). This result was in line with serum transaminase levels, which were slightly lower in the LPS-only group (Fig. 2, F and G).

  Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Effect of pioglitazone on ethanol plus LPS-induced liver injury. Photomicrographs of H&E sections of livers from rats treated as described under Materials and Methods. LPS was given at 24 h after ethanol and rats were sacrificed 24 h later (48 h after ethanol), 24 h after LPS (5 mg/kg i.v.) (A), 4 weeks of daily intragastric pioglitazone (500 μg/kg i.g., once daily) exposure and LPS for 24 h (B), 4 weeks of daily intragastric ethanol (5 g/kg) exposure and LPS for 24 h (original magnification, 100×) (C), 4 weeks of ethanol and LPS (400×) (D), and 4 weeks of ethanol + pioglitazone exposure and LPS for 24 h (100×) (E). Typical photomicrographs. F and G, blood samples were collected 24 h after LPS. Results are mean ± S.E.M. for four rats per group. *, p < 0.05 versus LPS. #, p < 0.05 versus 4 weeks of ethanol + LPS by ANOVA and Bonferroni's post hoc test.

In the 4-week ethanol group, LPS injection resulted in marked aggravation of these parameters with pronounced steatosis (Fig. 2, C and D). The histological changes were diminished by treatment with pioglitazone (500 μg/kg/day) (Fig. 2E). Compared with the control group, ALT value 24 h after LPS challenge was increased 3-fold to 1,200 ± 375 IU/l in the 4-week ethanol group. This increase was completely blunted by pioglitazone (Fig. 2G). Similar results were obtained with AST values (Fig. 2E).

Effect of Pioglitazone and Ethanol on LPS-Induced Increases in [Ca2+]i and TNF-α Production in Isolated Kupffer Cells. To evaluate the effect of pioglitazone on ethanol-induced Kupffer cell sensitization to LPS, we measured the LPS-induced increase of [Ca2+]i and production of TNF-α, as reported elsewhere (Enomoto et al., 1999). LPS (100 ng/ml) elicited a transient increase in [Ca2+]i of Kupffer cells isolated from control rats from basal level (36 ± 8 nM) to 81 ± 13 nM (Fig. 3, A and E). After the peak increase, [Ca2+]i declined rapidly returning to basal value. Pioglitazone treatment did not change the [Ca2+]i response (Fig. 3, B and E) In contrast, the peak [Ca2+]i elevation elicited by LPS was about 2- to 3-fold greater (227 ± 26 nM) in Kupffer cells obtained from rats given ethanol for 4 weeks (Fig. 3, C and E). It was also noted that, after the peak increase, [Ca2+]i started to decrease but remained elevated over 180 s (Fig. 3C). The increased [Ca2+]i response was blocked completely by coadministration of pioglitazone with ethanol for 4 weeks (Fig. 3, D and E).

  Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Effect of ethanol and pioglitazone on LPS-induced increases in intracellular Ca2+ in isolated Kupffer cells. Isolated Kupffer cells were cultured in 35-mm culture dishes at a density of 5 × 105 cells/dish for [Ca2+]i measurement. [Ca2+]i was measured using a microspectrometer with the fluorescent indicator, Fura-2. Changes in [Ca2+]i after addition of 100 ng/ml LPS, supplemented with 5% rat serum, are plotted. LPS was added to Kupffer cells from control rats (A and E), to Kupffer cells from rats treated with pioglitazone for 4 weeks before isolation (B and E), to Kupffer cells from rats treated with ethanol for 4 weeks before isolation (C and E), to Kupffer cells from rats treated with ethanol and pioglitazone for 4 weeks before isolation (D and E). Data are representative traces of experiments repeated four times (A-D). E, results are mean ± S.E.M., n = 4; *, p < 0.05 versus control; #, p < 0.05 versus 4 weeks of ethanol by ANOVA and Bonferroni's post hoc test.

Kupffer cell sensitization to LPS was further confirmed by TNF-α production, which demonstrated a 2-fold elevation in the 4-week ethanol group compared with the control (559 ± 71 versus 1,104 ± 110 pg/ml; p < 0.05) (Fig. 4). As expected, this increase in TNF-α was blunted by about 70% with pioglitazone. Kupffer cells obtained from the pioglitazone-only group produced TNF-α that did not differ from control (Fig. 4).

  Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Effect of ethanol and pioglitazone on LPS-induced TNF-α production by cultured Kupffer cells. Isolated Kupffer cells were cultured in 24-well plates at a density of 5 × 105 cells/well for TNF-α determination. After 24 h of preincubation, LPS (final concentration, 100 ng/ml in 5% rat serum) was added and incubation was continued for 4 h. TNF-α in medium was measured by ELISA. Basal TNF-α release after 4 h of incubation without LPS was 10 ± 2 pg/ml. Results are mean ± S.E.M., n = 4; *, p < 0.05 versus control; #, p < 0.05 versus 4 weeks of ethanol by ANOVA and Bonferroni's post hoc test.

Effect of Ethanol and Pioglitazone Treatment on CD14 Expression in Liver. Because CD14, a functional LPS/LBP receptor, is critical for signaling pathways leading to expression of cytokines, eicosanoides, and radical species in Kupffer cells, we measured CD14 with Western blotting. Liver from control rats expressed 55-kDa CD14 (Fig. 5, lane 1). Pioglitazone only did not alter CD14 level (lane 2). In marked contrast, the band was about 8-fold more intense in Kupffer cells from rats treated with ethanol for 4 weeks (lane 3). Furthermore, the effect of ethanol to enhance CD14 expression was markedly abrogated when pioglitazone was co-administered with ethanol for 4 weeks (lane 4).

  Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Effect of ethanol and pioglitazone on CD14 expression in liver. Protein extracts from control liver or livers from rats treated for 4 weeks with ethanol alone or with pioglitazone were analyzed by Western blotting using an anti-CD14 antibody. Specific bands for CD14 (55 kDa) are shown. Lane 1, livers from control rats; lane 2, livers from 4 weeks of pioglitazone; lane 3, livers from 4 weeks of ethanol; and lane 4, livers from 4 weeks of ethanol with pioglitazone. Data are representative of three individual experiments.

Effects of Ethanol and Pioglitazone on Gut Permeability and Portal LPS Levels. Because Kupffer cell sensitization is caused by LPS (Enomoto et al., 1999), we then examined the gut permeability, assessed by HRP (Fig. 6). Pioglitazone alone did not change the basal level of gut permeability. In marked contrast, 2 h after the final ethanol treatment in the 4-week group, gut permeability was increased dramatically, levels being about 10-fold higher than values from control rats; however, the ethanol-induced increase in gut permeability was not affected by treatment with pioglitazone (Fig. 6). LPS levels in portal blood did not differ between the ethanol-only and ethanol + pioglitazone groups (140 ± 51 versus 152 ± 80 pg/ml; N.S.)

  Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Effect of ethanol and pioglitazone treatment on gut permeability. Rats were treated with ethanol and pioglitazone for 4 weeks before experiments. Two hours after administration of final ethanol, segments of ileum were isolated and permeability to HRP was detected. Values are mean ± S.E.M. for four rats per group. *, p < 0.05 versus control by ANOVA and Bonferroni's post hoc test.

Effect of Pioglitazone on LPS-Induced TNF-α Production in Cultured Kupffer Cells. Because TNF-α plays a critical role in the pathogenesis of alcoholic liver injury, inhibition of TNF-α production from Kupffer cells is an obvious possibility that may explain the mechanism by which pioglitazone diminished liver injury due to chronic ethanol treatment. We therefore evaluated whether pioglitazone acted directly on Kupffer cells, thereby inhibiting TNF-α production.

After addition of LPS (100 ng/ml) to Kupffer cells isolated from normal rats, TNF-α production by Kupffer cells was increased (Fig. 7). Pioglitazone at 5 μM reduced the TNF-α production by Kupffer cells by about 25% (p < 0.05 versus LPS group).

  Fig. 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 7.

Effect of pioglitazone on LPS-induced TNF-α production in cultured Kupffer cells. Isolated Kupffer cells were cultured in 24-well plates at a density of 5 × 105 cells/well for TNF-α determination. After 24 h of preincubation, LPS (final concentration, 100 ng/ml in 5% rat serum) was added, and incubation was continued for 4 h. TNF-α in media was measured by ELISA. Basal TNF-α release after 4 h of incubation without LPS was 10 ± 2 pg/ml. Results are mean ± S.E.M., n = 4; *, p < 0.05 versus control; #, p < 0.05 versus LPS by ANOVA and Bonferroni's post hoc test.

Effect of Pioglitazone and TNF-α on Sensitization of Kupffer Cells to LPS in Vitro. It has been reported that specific agonists for PPAR-γ diminish insulin resistance in target cells. This effect is likely elicited by blockade of TNF- α-induced signaling pathways that interfere with the insulin-induced intracellular signal transduction. Analogously, we hypothesized that TNF-α potentiates Kupffer cell sensitization to LPS and that pioglitazone intervenes in the signaling pathways downstream of TNF-α receptors in Kupffer cells that control sensitization to LPS. To explore this possibility, a series of in vitro experiments using cultured Kupffer cells were performed.

First, to determine whether CD14 expression in Kupffer cells was regulated by TNF-α, immunocytochemical staining with anti-CD14 antibody was performed. As depicted in Fig. 8, Kupffer cells from control rats displayed a constitutive expression of CD14. Treatment with 10 ng/ml TNF-α for 24 h resulted in a pronounced increase in intensity of CD14 staining in Kupffer cells. Interestingly, inclusion of pioglitazone in the culture media during the TNF-α stimulation led to a diminished expression of CD14 to a level almost comparable to control expression (Fig. 8).

  Fig. 8.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 8.

Effect of TNF-α and pioglitazone on expression of CD14 in cultured Kupffer cells. Fluorescence micrographs. A, CD14 staining in control Kupffer cell. B, CD14 and actin staining in control Kupffer cell. C, CD14 staining in Kupffer cell treated for 24 h with TNF-α (10 ng/ml). D, CD14 and actin staining in Kupffer cell treated for 24 h with TNF-α. E, CD14 staining in Kupffer cell treated for 24 h with TNF-α (10 ng/ml) + pioglitazone. F, CD14 and actin staining in Kupffer cell treated for 24 h with TNF-α + pioglitazone. Actin staining was performed to identify the cell contour. Data are representative of three individual experiments. Original magnification, 400×.

Next, we evaluated whether TNF-α potentiates the LPS-induced increase in intracellular calcium response, a critical event leading to TNF-α production by Kupffer cells. As shown earlier, Kupffer cells from control rats exhibited a transient increase of [Ca2+]i (92 ± 10 nM) in response to 100 ng/ml LPS (Figs. 3 and 9A). In marked contrast, the LPS-induced [Ca2+]i response was 2- to 3-fold greater in Kupffer cells pretreated for 24 h with 10 ng/ml TNF-α (Fig. 9B). When pioglitazone was present in the culture medium, this LPS-induced enhancement of [Ca2+]i response was almost completely abrogated.

  Fig. 9.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 9.

Effect of TNF-α on LPS-induced increase in [Ca2+]i and TNF-α production by cultured Kupffer cells. Kupffer cells were isolated and cultured for 24 h with and without TNF-α (10 ng/ml). Subsequently, cells were washed vigorously with phosphate-buffered saline and challenged for 24 h with LPS (100 ng/ml). A and B, LPS-induced [Ca2+]i response was measured as described under Materials and Methods. C, TNF-α in media was measured by ELISA. TNF-α release after 4 h of incubation without LPS was 10 ± 2 pg/ml. Results are mean ± S.E.M., n = 4; *, p < 0.05 versus control [TNF-α(-)], by ANOVA and Bonferroni's post hoc test.

Furthermore, LPS-induced TNF-α production by isolated Kupffer cells was compared between groups cultured for 24 h in the presence or absence of TNF-α (10 ng/ml). As expected, Kupffer cells cultured in the presence of TNF-α produced 30% more TNF-α in response to LPS (100 ng/ml) than control cells that were cultured in the absence of TNF-α (Fig. 9C). The addition of pioglitazone in the culture media during the TNF-α stimulation resulted in a complete inhibition of the increase in TNF-α production by Kupffer cells. In addition, pioglitazone increased the amount of tristetraprolin, a CCCH zinc finger protein known to destabilize TNF-α mRNA (Fig. 10).

  Fig. 10.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 10.

Effect of TNF-α and pioglitazone on TTP by cultured Kupffer cells. Protein extracts from control Kupffer cell, pioglitazone-treated Kupffer cell, TNF-α-treated Kupffer cell, and pioglitazone plus TNF-α-treated Kupffer cell were analyzed by Western blotting using an anti-rat TTP antibody. Specific bands for TTP are shown. Lane 1, control Kupffer cells; lane 2, Kupffer cells treated with pioglitazone; lane 3, Kupffer cells treated with TNF-α; and lane 4, Kupffer cells treated with pioglitazone and TNF-α. Data are representative of three individual experiments.

A PPAR-γ Agonist Pioglitazone Prevents Alcohol-Induced Liver Injury through Suppression of TNF-α Production. It has been established that sensitization of Kupffer cells to LPS and consequent overproduction of TNF-α play a pivotal role in the pathogenesis of alcohol liver disease (Stahnke et al., 1991; Martinez et al., 1992; Enomoto et al., 1998). Therefore, in this study, we used a model of alcohol-induced liver injury based on sensitization of Kupffer cells (Enomoto et al., 1999). This model achieves pathological changes in the liver (e.g., steatosis, inflammation, and necrosis) that resemble alterations found in clinical alcoholic liver disease (Fig. 1). In this setting, Kupffer cells isolated from rats exposed to ethanol chronically were sensitized to LPS as evidenced by enhanced transient increase in [Ca2+]i and TNF-α production (Fig. 3). In addition, CD14 expression in livers of the ethanol-treated rats was greatly enhanced (Fig. 5). Consequently, LPS administration into rats treated with ethanol for 4 weeks led to marked aggravation of liver injury (Fig. 2).

It was shown that a PPAR-γ agonist, pioglitazone, prevented ethanol-induced liver injury almost completely (Fig. 1). This effect is at least in part attributable to reduced TNF-α production because pioglitazone blunted markedly TNF-α production by Kupffer cells from ethanol-treated animals (Fig. 4). PPAR-γ is a member of the nuclear receptor family of transcription factors. Because Kupffer cells, the largest population of macrophage linage in the body, contain PPAR-γ (Ricote et al., 1999), we explored the possibility that pioglitazone directly acted on Kupffer cells, thereby preventing TNF-α production. As shown in Fig. 7, pioglitazone suppressed TNF-α production in Kupffer cells. This result agrees with an earlier work by Uchimura showing that PPAR-γ ligands inhibited TNF-α production from macrophages (Uchimura et al., 2001). They suggested that this inhibition occurred at the transcriptional level. Our results may add to a new mechanism for the action of pioglitazone to inhibit TNF-α production because pioglitazone increased expression of TTP, a CCCH zinc finger protein shown to inhibit TNF-α-induced TNF-α production from macrophages by destabilizing its mRNA (Carbollo et al., 1998). Furthermore, the fact that pioglitazone destabilizes TNF-α mRNA gives a good basis for the use of this type of drug for treatment of alcohol-induced liver injury because it was recently reported that chronic ethanol results in stabilization of TNF-α mRNA (Kishore et al., 2001).

One could, however, argue that the preventive effect of pioglitazone against alcoholic liver could not be attributable solely to the direct suppression of TNF-α because the inhibition was not perfect (25% reduction as shown in Fig. 7). TNF-α has a wide range of bioactivity, and the regulatory mechanisms of TNF-α production and its intracellular signaling have been studied extensively (Papadakis and Targan, 2000). It is suggested that TNF-α acts on macrophages/monocytes to promote its own synthesis and secretion (Carbollo et al., 1998). Indeed, the results of this study indicate that in the presence of TNF-α, the production of TNF-α from Kupffer cells was about 30% higher than that in its absence, confirming our recent observation (Fig. 9C; Enomoto et al., 2002).

The autocrine acceleration of TNF-α production seems to be of primary importance for the pioglitazone action in prevention of alcohol-induced liver damage, given the fact that pioglitazone treatment in vivo abrogated ethanol-induced liver injury. Furthermore, because Kupffer cells reside strategically in the narrow sinusoidal space, one can envision that the liver microenvironment favors this autocrine activation to operate and perpetuate in an efficient way. It is thus postulated that the initial inhibition of TNF-α production, although not complete, culminates in sufficient suppression of TNF-α synthesis during a long-term ethanol load that might account for the hepatoprotective effect of pioglitazone.

Pioglitazone Prevents Kupffer Cell Sensitization to LPS. It is notable that Kupffer cell sensitization to LPS was almost completely prevented in the group treated for 4 weeks with ethanol and pioglitazone, given that Kupffer cell response to LPS, as evaluated by intracellular calcium increase, was diminished to a level comparable with control (Fig. 3). As we reported previously, ethanol-induced sensitization of Kupffer cells is caused by gut-derived endotoxin and that sensitization in Kupffer cells is caused by an increase in CD14 (Watanabe et al., 1990). To support this notion, Kupffer cell sensitization caused by long-term ethanol treatment was blocked by antibiotics in vivo (Enomoto et al., 1999). Moreover, Nanji et al. (1993) reported that a good correlation between blood endotoxin and liver pathology was observed in the Tsukamoto-French model (Ricote et al., 1999). Therefore, we investigated the effect of pioglitazone on gut permeability. Pioglitazone, however, did not alter gut permeability (Fig. 6). Furthermore, LPS concentrations in portal blood of the both groups did not differ. These data indicate that Kupffer cells in both groups were exposed to similar concentrations of LPS, making it unlikely that pioglitazone elicited its effect through regulation of portal LPS concentrations.

Alternatively, it seems likely that TNF-α itself regulates Kupffer cells sensitization because TNFα up-regulated expression of CD 14 protein in Kupffer cells (Fig. 8) and the intracellular calcium response to LPS. Pioglitazone blocked completely the TNF-α-induced CD14 up-regulation in Kupffer cells as well as the increased intracellular calcium response in response to LPS (Fig. 9).

The precise mechanisms by which PPAR-γ ligands/agonists interfere with the TNF-α-induced signal transduction, thereby abolishing sensitization to LPS and TNF-α secretion, are yet to be elucidated. The possibilities that pioglitazone may oppose TNF-α-induced reduction of its receptor PPAR-γ and/or that pioglitazone acted on hepatocytes to enhance resistance to TNF-α may also be taken into account.

These results show that pioglitazone prevents alcoholic liver injury through suppression of TNF-α production and Kupffer cell sensitization to LPS. PPAR-γ agonists are now widely used for treatment of diabetes mellitus, and they may prove useful as a therapeutic modality in the treatment of alcohol-induced liver injury. Furthermore, because nonalcoholic steatohepatitis is characterized by an ongoing inflammation associated with overexpression of proinflammatory cytokines such as TNF-α from Kupffer cells (Neuschwander-Tetri and Caldwell, 2003), it seems most likely that pioglitazone is also effective in the treatment of nonalcoholic steatohepatitis.

Footnotes

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • DOI: 10.1124/jpet.102.047217.

  • ABBREVIATIONS: LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-α; PPAR, peroxisome proliferator-activated receptor; i.g., intragastrically; AST, aspartate transaminase; ALT, alanine aminotransferase; [Ca2+]i, intracellular calcium concentration; AM, acetoxymethyl ester; ELISA, enzyme-linked immunosorbent assay; TTP, tristetraprolin; ANOVA, analysis of variance; HRP, horseradish peroxidase.

    • Received March 17, 2003.
    • Accepted May 27, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    Bergmeyer HU (1988) Methods of Enzymatic Analysis, Academic Press, New York.
  2. ↵
    Carbollo E, Lai WS, and Blackshear PJ (1998) Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin. Science (Wash DC) 281: 1001-1004.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Carter EA, Harmatz PR, Udall JN, and Walker WA (1987) Barrier defense function of the small intestine: effect of ethanol and acute burn trauma. Adv Exp Med Biol 216: 829-833.
    OpenUrl
  4. ↵
    Decker T, Lohmann-Matthes ML, Karck U, Peters T, and Decker K (1989) Comparative study of cytotoxicity; tumor necrosis factor, and prostaglandin release after stimulation of rat Kupffer cell, murine Kupffer cells and murine inflammatory liver macrophages. J Leukoc Biol 45: 139-146.
    OpenUrlAbstract
  5. ↵
    Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Brenner DA, and Thurman RG (1998) Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology 115: 443-451.
    OpenUrlCrossRefPubMed
  6. ↵
    Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, and Sato N (2002) Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-α production. Gastroenterology 123: 291-300.
    OpenUrlCrossRefPubMed
  7. ↵
    Enomoto N, Yamashina S, Kono H, Schemmer P, Rivera CA, Enomoto A, Nishiura T, Nishimura T, Brenner DA, and Thurman RG (1999) Development of a new, simple rat model of early alcohol-induced liver injury based on sensitization of Kupffer cells. Hepatology 29: 1680-1689.
    OpenUrlCrossRefPubMed
  8. ↵
    Grynkiewicz G, Poenie M, and Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Hijioka T, Sato N, Matsumura T, Yoshihara H, Takei Y, Fukui H, Oshita M, Kawano S, and Kamada T (1991) Ethanol-induced disturbance of hepatic microcirculation and hepatic hypoxia. Biochem Pharmacol 40: 1551-1557.
    OpenUrl
  10. ↵
    Hofman C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, and Spiegelman BM (1994) Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270.
    OpenUrlCrossRefPubMed
  11. ↵
    Iimuro Y, Gallucci RM, Luster MI, Kono H, and Thurman RG (1997) Antibodies to tumor necrosis factor-α attenuate hepatic necrosis and inflammation due to chronic exposure to ethanol in the rat. Hepatology 26: 1530-1537.
    OpenUrlCrossRefPubMed
  12. ↵
    Jiang C, Ting AT, and Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature (Lond) 391: 82-86.
    OpenUrlCrossRefPubMed
  13. ↵
    Kishore R, McMullen MR, and Nagy LE (2001) Stabilization of tumor necrosis factor a mRNA by chronic ethanol. J Biol Chem 276: 41930-41937.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Martinez F, Abril ER, Earnest DL, and Watson RR (1992) Ethanol and cytokine secretion. Alcohol 9: 455-458.
    OpenUrlCrossRefPubMed
  15. ↵
    McCuskey RS, Eguchi H, Nishida J, Urbaschek R, and Urbaschek B (1993) Effects of ethanol alone or in combination with infection, toxins or drug of abuse on the hepatic microcirculation. Adv Biol Sci 86: 227-234.
    OpenUrl
  16. ↵
    Murase K, Odaka H, Suzuki M, Tayuki N, and Ikeda H (1998) Pioglitazone time-dependently reduces tumor necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 41: 257-264.
    OpenUrlCrossRefPubMed
  17. ↵
    Nanji AA, Khettry U, Sadrzadeh SM, and Yamanaka T (1993) Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, pros-taglandin E2, leukotriene B4 and thromboxane B2. Am J Pathol 142: 367-373.
    OpenUrlPubMed
  18. ↵
    Nanji AA, Mendenhall CL, and French SW (1989) Beef fat prevents alcoholic liver disease in the rat. Alcohol Clin Exp Res 13: 15-19.
    OpenUrlCrossRefPubMed
  19. ↵
    Neuschwander-Tetri BA and Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37: 1202-1219.
    OpenUrlCrossRefPubMed
  20. ↵
    Nolan JP (1981) Endotoxin, reticuloendothelial function and liver injury. Hepatology 1: 458-465.
    OpenUrlCrossRefPubMed
  21. ↵
    Oshita M, Sato N, Yoshihara H, Takei Y, and Hijioka T (1992) Ethanol-induced vasoconstriction causes focal hepatocellular injury in the isolated perfused rat liver. Hepatology 16: 1007-1013.
    OpenUrlPubMed
  22. ↵
    Papadakis KA and Targan SR (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119: 1148-1157.
    OpenUrlCrossRefPubMed
  23. Pertoft H and Smedsrod B (1982) Separation and characterization of liver cells, in Cell Separation: Methods and Selected Applications (Pretlow TG 2nd and Pretlow TP eds) vol 4, pp 1-24, Academic Press, New York.
    OpenUrl
  24. ↵
    Ricote M, Huang JT, Welch JS, and Glass CK (1999) The peroxisome proliferator-activated receptor (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol 66: 733-739.
    OpenUrlAbstract
  25. ↵
    Saltiel AR and Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Schulze-Osthoff K, Beyaert R, Vandervoorde V, Haegeman G, and Fiers W (1993) Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-induced effects of TNF. EMBO (Eu Mol Biol Organ) J 12: 3095-3104.
    OpenUrlPubMed
  27. ↵
    Stahnke LL, Hill DB, and Allen JI (1991) TNFα and IL-6 in alcoholic liver disease, in Cells of the Hepatic Sinusoid (Wisse E, Knock DL, and McCuskey RS eds) vol 3, pp 472-475, Kupffer Cell Foundation, Leiden.
    OpenUrl
  28. ↵
    Shibayama Y, Asaka S, and Nakata K (1991) Endotoxin hepatotoxicity augmented by ethanol. Exp Mol Pathol 55: 196-202.
    OpenUrlCrossRefPubMed
  29. ↵
    Thurman RG, Paschal DL, Abu-Murad C, Pekkanen L, Bradford BU, Bullock KA, and Glassman EB (1982) Swift increase in alcohol metabolism (SIAM) in the mouse: comparison of the effect of short-term ethanol treatment on ethanol elimination in four inbred strains. J Pharmacol Exp Ther 223: 45-52.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Uchimura K, Nakamuta M, Enjoji M, Irie T, Sugimoto R, Muta T, Iwamoto H, and Nawata H (2001) Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology 33: 91-99.
    OpenUrlCrossRefPubMed
  31. ↵
    Wang J-F, Greenberg SS, and Spitzer JJ (1995) Chronic alcohol administration stimulates nitric oxide formation in rat liver with or without pretreatment by lipopolysaccharide. Alcohol Clin Exp Res 19: 387-393.
    OpenUrlCrossRefPubMed
  32. ↵
    Watanabe S, Hirose M, Ueno T, Kominami E, and Namihisa T (1990) Integrity of the cytoskeletal system in important for phagocytosis by Kupffer cells. Liver 10: 249-254.
    OpenUrlPubMed
  33. ↵
    Watanabe N, Suzuki J, and Kobayashi Y (1996) Role of calcium in tumor necrosis factor-α produced by activated macrophages. J Biochem 120: 1190-1195.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Wendell GD and Thurman RG (1979) Effect of ethanol concentration on rates of ethanol elimination in normal and alcohol-treated rats in vivo. Biochem Pharmacol 28: 273-279.
    OpenUrlCrossRefPubMed
  35. ↵
    Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, and Thurman RG (1999) Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. Gastroenterology 117: 942-952.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 306 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 306, Issue 3
1 Sep 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prevention of Ethanol-Induced Liver Injury in Rats by an Agonist of Peroxisome Proliferator-Activated Receptor-γ, Pioglitazone
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Prevention of Ethanol-Induced Liver Injury in Rats by an Agonist of Peroxisome Proliferator-Activated Receptor-γ, Pioglitazone

Nobuyuki Enomoto, Yoshiyuki Takei, Miyoko Hirose, Akira Konno, Tomoyoshi Shibuya, Shujiro Matsuyama, Satoko Suzuki, Kenichi Ikejima Tsuneo Kitamura and Nobuhiro Sato
Journal of Pharmacology and Experimental Therapeutics September 1, 2003, 306 (3) 846-854; DOI: https://doi.org/10.1124/jpet.102.047217

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Prevention of Ethanol-Induced Liver Injury in Rats by an Agonist of Peroxisome Proliferator-Activated Receptor-γ, Pioglitazone

Nobuyuki Enomoto, Yoshiyuki Takei, Miyoko Hirose, Akira Konno, Tomoyoshi Shibuya, Shujiro Matsuyama, Satoko Suzuki, Kenichi Ikejima Tsuneo Kitamura and Nobuhiro Sato
Journal of Pharmacology and Experimental Therapeutics September 1, 2003, 306 (3) 846-854; DOI: https://doi.org/10.1124/jpet.102.047217
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • H2S Overproduction and Colonic Hypomotility in DM
  • A Novel Long-Acting GLP-2, HM15912, for Short Bowel Syndrome
  • MIP3a in Progressive Renal Injury Associated With Obesity
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics